2021: The Year in Review
- ByInvesting.com-
By Peter Nurse, Liz Moyer, Sam Boughedda and Yasin EbrahimInvesting.com -- The year 2021 is rapidly drawing to a close, and while it has been a significant improvement,...
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
By Peter Nurse, Liz Moyer, Sam Boughedda and Yasin EbrahimInvesting.com -- The year 2021 is rapidly drawing to a close, and while it has been a significant improvement,...
Cambridge Investment Research Advisors Inc. boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 27.5% during the 3rd quarter, according to its most recent disclosure...
Nordea Investment Management AB bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to the company in its most recent Form 13F filing...
LLY, one of the best-performing pharma stocks in 2021, was down over 6% in the first week of the new year.Wall Street concurs that innovation across its core therapeutic areas has...
January 2022 could be a good time to review financial goals and start investing regularly. Long-term investors know that time is always on their side.Here’s why: Let’s assume you...
Compiled by Jesse CohenWith just one trading day left this year, Wall Street’s major indices are on track to close 2021 at record highs as optimism over the global economy appears...
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Neutral | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2.23 | 2.32 | 2.18 | -0.010 | -0.45% | 682.02K | Toronto | |||
| 4.04 | 4.19 | 3.96 | -0.080 | -1.94% | 43.75K | Toronto | |||
| 2.60 | 2.80 | 2.59 | -0.06 | -2.26% | 58.60K | Toronto | |||
| 2.84 | 2.88 | 2.84 | -0.04 | -1.39% | 218.95K | Toronto | |||
| 40.63 | 40.88 | 40.46 | -0.26 | -0.64% | 159.63K | Toronto | |||
| 66.30 | 66.65 | 65.20 | -0.55 | -0.82% | 854.22K | Toronto | |||
| 108.51 | 109.04 | 106.60 | -1.15 | -1.05% | 614.98K | Toronto | |||
| 45.96 | 46.60 | 45.56 | -0.55 | -1.18% | 103.52K | Toronto | |||
| 2.74 | 2.89 | 2.71 | -0.2400 | -8.05% | 2.57M | TSXV | |||
| 0.18 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Toronto | |||
| 57.63 | 59.27 | 56.53 | +0.53 | +0.93% | 174.13K | Toronto | |||
| 154.00 | 155.73 | 153.27 | -1.70 | -1.09% | 2.96K | Toronto | |||
| 161.47 | 162.70 | 159.89 | -0.72 | -0.44% | 223.76K | Toronto | |||
| 66.17 | 66.96 | 65.44 | -1.26 | -1.87% | 201.04K | Toronto | |||
| 40.61 | 41.12 | 40.47 | -0.46 | -1.12% | 2.69M | Toronto |